The results showed that in high risk patients with T2D liraglutide reduced the risk of MACE by 13% (primary endpoint included cardiovascular death, non-fatal myocardial infarction (MI), and non-fatal stroke) ( In the ELIXA and the EXSCEL trials, GLP-1RAs (once daily lixisenatide and once weekly exenatide, respectively) didnt provide benefit in MACE reduction compared to placebo, but were non-inferior to placebo for the primary composite outcome of MACE
KLOW Blend Calculator and Educational Peptide Tools GoalBMI Wellness provides educational calculators to help patients understand how prescribed peptide doses, vial concentrations, injection volumes and syringe units relate to one another
Katz BJ et al
Sections were incubated with Schiff's reagent (Sigma-Aldrich, St
However, side effects of GLP-1 RAs, particularly those affecting the gastrointestinal system, may limit their use in patients with IBD
Tesamorelin Side Effects and Dose Relationship Most tesamorelin side effects are mild and related to dose or injection technique